Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2021

06.07.2021 | short review

New trends in autologous and allogeneic stem cell transplantation—an update from the annual ASH meeting 2020

verfasst von: PD Dr. Alexandra Böhm, Prof. Dr. Felix Keil

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

At the 62nd annual meeting of the American Society of Hematology (ASH) 2020—which took place virtually for the first time—numerous clinical studies and research results were presented. The latest trends and exciting developments in the field of stem cell transplantation can be found in the following article, e. g. how transplantations with a mismatch donor can be safely performed, important studies regarding MDS and ALL patients, a promising second-line treatment in chronic GVHD, why the nutritional status and the microbiome should be part of the pre-transplant work-up and that lifelong follow-up for children and young adolescents after an allogeneic transplantation is essential.
Literatur
1.
Zurück zum Zitat Shaw BE, Jimenez-Jimenez A, Burns LJ, et al. Bridging the gap in access to transplant for Underserved minority patients using mismatched unrelated donors and post-transplant cyclophosphamide: a national marrow donor program/be the match (NMDP/BTM) initiative. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 297. Shaw BE, Jimenez-Jimenez A, Burns LJ, et al. Bridging the gap in access to transplant for Underserved minority patients using mismatched unrelated donors and post-transplant cyclophosphamide: a national marrow donor program/be the match (NMDP/BTM) initiative. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 297.
2.
Zurück zum Zitat Nakamura R, Saber W, Martens MJ, et al. A multi-center biologic assignment trial comparing reduced intensity allogeneic hematopoietic cell transplantation to hypomethylating therapy or best supportive care in patients aged 50–75 with advanced myelodysplastic syndrome: blood and marrow transplant clinical trials network study 1102. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 75. Nakamura R, Saber W, Martens MJ, et al. A multi-center biologic assignment trial comparing reduced intensity allogeneic hematopoietic cell transplantation to hypomethylating therapy or best supportive care in patients aged 50–75 with advanced myelodysplastic syndrome: blood and marrow transplant clinical trials network study 1102. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 75.
3.
Zurück zum Zitat Giebel S, Labopin M, Houhou M, et al. Comparison of reduced intensity conditioning—allogeneic HCT and autologous HCT for elderly patients with acute lymphoblastic leukemia. An analysis from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 614. Giebel S, Labopin M, Houhou M, et al. Comparison of reduced intensity conditioning—allogeneic HCT and autologous HCT for elderly patients with acute lymphoblastic leukemia. An analysis from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 614.
4.
Zurück zum Zitat Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib (RUX) vs best available therapy (BAT) in patients with steroid-refractory/steroid-dependent chronic graft-vs-host disease (cGVHD): primary findings from the phase 3, randomized REACH3 study. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 77. Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib (RUX) vs best available therapy (BAT) in patients with steroid-refractory/steroid-dependent chronic graft-vs-host disease (cGVHD): primary findings from the phase 3, randomized REACH3 study. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 77.
5.
Zurück zum Zitat Perrot A, Lauwers-Cances V, Cazaubiel T, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 143. Perrot A, Lauwers-Cances V, Cazaubiel T, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 143.
6.
Zurück zum Zitat Tucci A, Re A, Pagani C, et al. Rituximab with dose-adjusted EPOCH (R-DA-EPOCH) with or without autologous stem cell transplantation (ASCT) as first line treatment in patients with aggressive B‑cell lymphoma with MYC and BCL‑2 and/or BCL‑6 gene rearrangements or increase copy number. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 2131. Tucci A, Re A, Pagani C, et al. Rituximab with dose-adjusted EPOCH (R-DA-EPOCH) with or without autologous stem cell transplantation (ASCT) as first line treatment in patients with aggressive B‑cell lymphoma with MYC and BCL‑2 and/or BCL‑6 gene rearrangements or increase copy number. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 2131.
7.
Zurück zum Zitat Brauer D, Backhaus D, Vucinic V, et al. Prognostic impact of nutritional status at diagnosis and weight changes in acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 2431. Brauer D, Backhaus D, Vucinic V, et al. Prognostic impact of nutritional status at diagnosis and weight changes in acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation. 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 2431.
8.
Zurück zum Zitat Sallfors Holmqvist A, Chen Y, Wu J, et al. Severe/life-threatening/fatal chronic health conditions (CHcs) after allogeneic blood or marrow transplantation (BMT) in childhood—a report from the BMT survivor study (BMTSS). 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 69. Sallfors Holmqvist A, Chen Y, Wu J, et al. Severe/life-threatening/fatal chronic health conditions (CHcs) after allogeneic blood or marrow transplantation (BMT) in childhood—a report from the BMT survivor study (BMTSS). 62nd ASH Annual Meeting, December 5–8, 2020; Abstract No. 69.
Metadaten
Titel
New trends in autologous and allogeneic stem cell transplantation—an update from the annual ASH meeting 2020
verfasst von
PD Dr. Alexandra Böhm
Prof. Dr. Felix Keil
Publikationsdatum
06.07.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00725-1